Shirin David

ABC's GOOD MORNING AMERICA to Reveal and Premiere the New MENUDO

Retrieved on: 
월요일, 3월 6, 2023
Good Morning America, Shirin David, Music, Safety, Orchard, Nightclub

MIAMI, March 6, 2023 /PRNewswire-PRWeb/ -- From virtual castings that began in August of 2022 to in-person auditions in Puerto Rico, Los Angeles, and Miami, the members of the new MENUDO are now slated to premiere their first single and video "Mi Amore" off their upcoming debut album.

Key Points: 
  • Mario Lopez's highly anticipated world reveal of the new MENUDO will take place on Monday, March 20, 2023.
  • MENUDO's single "Mi Amore" will be released by Mistar Entertainment and distributed worldwide by The Orchard in both English and Spanish to coincide with the group's debut on Good Morning America and the release of their music video.
  • The five boys we selected gelled together instantly, and the music they've created has exceeded all of our expectations.
  • I think we have several massive hits, and I'm more excited than ever to introduce these boys to the world in two weeks."

Martin Searle Solicitors Employment Law Team launch their campaign "#MeToo Matters" to Stamp Out Sexual Harassment in the Workplace in March 2023

Retrieved on: 
월요일, 3월 6, 2023
Ageing, Equality, Macdonald, Incidence, Labour law, Workplace, SRA, Solicitors Regulation Authority, Shirin David, Woman, United Kingdom, NDA, Trade union, HR, EHRC, McDonald's, Equality and Human Rights Commission, FAQ, Employment, Work, Government Equalities Office, Indian Residential Schools Settlement Agreement, Nursing, Property management, Private investigator

BRIGHTON, The United Kingdom, March 6, 2023 /PRNewswire-PRWeb/ -- The Martin Searle Solicitors Employment Law team have found that sexual harassment in the workplace remains a problem, particularly now people have returned to work and are once again attending business conferences and work social events.

Key Points: 
  • BRIGHTON, The United Kingdom, March 6, 2023 /PRNewswire-PRWeb/ -- The Martin Searle Solicitors Employment Law team have found that sexual harassment in the workplace remains a problem, particularly now people have returned to work and are once again attending business conferences and work social events.
  • And the concerns by the EHRC about their handling of sexual harassment complaints made by staff in the UK.
  • 48% of those who reported their workplace sexual harassment were asked to sign a Non-Disclosure Agreement (NDA) in relation to their experience.
  • Martin Searle Solicitors have produced a series of free factsheets, case studies and FAQs for employers and employees covering sexual harassment at work.

Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director

Retrieved on: 
화요일, 2월 28, 2023
Biotechnology, Pharmaceutical, Health, ODT, Ipilimumab, Aripiprazole, Therapy, Shirin David, Shareholder, University, Bachelor of Science, NS3, Bristol Myers Squibb, Nivolumab, Drug development, Acquisition, Yale school, CGRP, Neurology, Calcitonin, Physiology, Daclatasvir, Wake Forest School of Medicine, Medical director, Sale, Yale School of Medicine, Psychiatry, NS5A, DNAA, Pharmaceutical industry, Pfizer, Neuroscience

(RVNC), announced today the appointment of Dr. Vlad Coric, M.D., to its Board of Directors, effective March 1, 2023.

Key Points: 
  • (RVNC), announced today the appointment of Dr. Vlad Coric, M.D., to its Board of Directors, effective March 1, 2023.
  • The company also announced that long-standing director Philip Vickers has decided that he will be retiring from the Board effective immediately prior to the company’s 2023 Annual Meeting of Stockholders.
  • “His appointment comes at a dynamic time for Revance as we accelerate our commercial growth in aesthetics and look to advance our significant opportunity in therapeutics.
  • Previously, Dr. Coric was the Group Director, Neuroscience and Oncology Global Clinical Research, and Medical Director, Neuroscience Global Clinical Research, at Bristol-Myers Squibb Company.

ABVC BioPharma Provides 2023 Pipeline Update

Retrieved on: 
화요일, 2월 28, 2023
Medicine, Shirin David, Cancer, Memorial Sloan Kettering Cancer Center, Medical Center, IND, CSMC, Myelodysplastic syndrome, Trial of the century, Stanford University Medical Center, Center for Drug Evaluation and Research, Safety, Massachusetts General Hospital, Patient, Central nervous system, Psychiatry, Hospital, Phase, University of California, San Francisco, Grammatical mood, University, Depression, UCSF, Regulation, Research, San Francisco, CNS, MGH, Cedars-Sinai Medical Center, US, Pancreatic cancer, Visual acuity, Lung cancer, FDA, Ophthalmology, Bupropion, Harvard Medical School, Division, ADHD, MDD, Pharmaceutical industry, Nursing, Phase II

FREMONT, CA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today provided an update to drug and medical device developments expected in 2023.

Key Points: 
  • FREMONT, CA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today provided an update to drug and medical device developments expected in 2023.
  • ABVC expects to initiate the Phase II study in the fourth quarter of 2023 and then compare the results to Wellbutrin XL, a commonly used medicine to treat cancer patients suffering with depression.
  • The clinical study for ABV-1702 for myelodysplastic syndrome is expected to start in Q4 of 2023.
  • In addition, ABVC intends to submit ABV-1703’s Phase II clinical trial IND to the Taiwan FDA after commencing clinical trials in the United States.

NEO Battery Materials Provides Corporate Updates on NBM America and Silicon Anode Product Evaluation & Pipelines

Retrieved on: 
화요일, 2월 21, 2023
Carbon, NMC, NDA, Acquisition, Shirin David, CNT, LFP, EV, Silicon, Site Selection, Accredited Economic Development Organization, Resource Access Control Facility, Economic development, NEO, R, Electric battery, Fine chemical

As announced on January 25, 2023, NEO Battery Materials is planning to establish NBM America Ltd. as a private subsidiary company in Ohio, U.S.

Key Points: 
  • As announced on January 25, 2023, NEO Battery Materials is planning to establish NBM America Ltd. as a private subsidiary company in Ohio, U.S.
  • The expansion objective is to initiate business development in the growing North American EV battery supply chain and support collaborative interactions and opportunities with U.S.-based NDA partners.
  • To expedite the timeline for joint venture opportunities, NEO plans to establish an R&D Center to manufacture silicon anode samples for North American battery manufacturers.
  • The Company also initiated discussions with U.S. venture capital firms to secure series funding for NBM America, and NEO aims to develop complementary value-enhancing projects.

Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye Drops for Reversal of Mydriasis

Retrieved on: 
월요일, 2월 13, 2023
MBA, MIRA, New Drug Application, Presbyopia, RM, NDA, Patient, PDUFA, File, Frustration, Shirin David, Ageing, OCUP, Food, Pupil, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry

The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of September 28, 2023.

Key Points: 
  • The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of September 28, 2023.
  • “The FDA’s acceptance of the NDA submission and PDUFA date in late September for Nyxol sets the stage for an exciting 2023”, said Mina Sooch, MBA, founder and CEO of Ocuphire Pharma.
  • If approved later this year, Nyxol eye drops will be the first prescription reversal drop available for patients in the US.
  • In addition, the positive MIRA-4 pediatric trial results support a potential broader label for Nyxol in RM to include subjects aged 3 and older.

Veristat Supported Eight Regulatory Approvals in 2022, the Majority for Therapies Designed to Treat Rare Diseases

Retrieved on: 
화요일, 2월 14, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Genetics, Clinical Trials, Life, Shanda, MAA, Bangladesh Technical Education Board, NIH, Clinical trial, Shirin David, EMA, European Medicines Agency, Knowledge, Marketing, Disease, US Foods, BLA, Data collection, Western world, Pharmaceutical industry

One Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) was approved, and collectively most of the approvals were for therapies targeting a rare disease.

Key Points: 
  • One Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) was approved, and collectively most of the approvals were for therapies targeting a rare disease.
  • In the last three years, Veristat teams have:
    Celebrated the success of clients receiving more than 25 regulatory approvals for marketing applications prepared by Veristat teams, 75% of which were for rare disease therapies.
  • “Rare disease research presents many challenges for trial design and regulatory strategy,” stated John Balser, Ph.D., Veristat Founder, President, and Chief Statistical Officer.
  • Our creative approaches have helped them overcome daunting evidentiary and regulatory hurdles to gain swift and successful therapy approval.”

Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products

Retrieved on: 
월요일, 1월 23, 2023
Biotechnology, Pharmaceutical, Optical, Medical Supplies, Surgery, Health, FDA, Clinical Trials, Shirin David, NDA, Acquisition, EBITDA, Pharmaceutical industry

Pursuant to the terms of an asset purchase agreement, Harrow paid $130 million at closing, with an additional milestone payment due upon the commercial availability of TRIESENCE.

Key Points: 
  • Pursuant to the terms of an asset purchase agreement, Harrow paid $130 million at closing, with an additional milestone payment due upon the commercial availability of TRIESENCE.
  • Harrow and the seller have entered into an estimated six-month transition period during which the seller will continue to sell the products in the U.S. and transfer all net profits from the products to Harrow.
  • Upon the transfer of a product NDA, Harrow will assume control over all U.S. market activities for the subject product.
  • Harrow believes that both net revenues and adjusted EBITDA should grow further during 2024 and for at least three to five years thereafter.

Hunt Scanlon Ventures Names Erik Boender as Chief Operating Officer

Retrieved on: 
화요일, 2월 14, 2023
Research, Shirin David, M&A, Acquisition, EBITDA, Marketing, Management, Financial services, Operation

GREENWICH, Conn., Feb. 14, 2023 /PRNewswire/ -- Hunt Scanlon Ventures – the M&A advisory firm serving the executive recruiting and human capital sectors – announced today that Erik Boender has been named Chief Operating Officer.

Key Points: 
  • GREENWICH, Conn., Feb. 14, 2023 /PRNewswire/ -- Hunt Scanlon Ventures – the M&A advisory firm serving the executive recruiting and human capital sectors – announced today that Erik Boender has been named Chief Operating Officer.
  • "We are delighted to move Erik into this elevated capacity in our M&A business," said Cody Crook, Managing Director of Hunt Scanlon Ventures.
  • Mr. Boender will also serve in a dual capacity as Chief Operating Officer for Hunt Scanlon Media, where he has played an integral role in day-to-day operations as Vice President of Operations since 2018.
  • Hunt Scanlon Ventures is an M&A advisory firm focused on the human capital markets.

CobbleStone Software Releases New Guide on Understanding the Basics of NDAs

Retrieved on: 
화요일, 2월 7, 2023
Gentlemen's agreement, Cobblestone, Shirin David, CLM, Marketing, NDA, Element, SPARK, Contact, Software, Crash, Real estate

PRINCETON, N.J., Feb. 7, 2023 /PRNewswire-PRWeb/ -- CobbleStone Software – the recognized Leader in contract lifecycle management (CLM) according to the SPARK Matrix™ 2022 report – has released a comprehensive guide detailing the importance of Non-Disclosure Agreements (NDAs) and how they relate to many business relationships.

Key Points: 
  • CobbleStone Software has published a free guide highlighting Non-Disclosure Agreements and their importance in business processes.
  • PRINCETON, N.J., Feb. 7, 2023 /PRNewswire-PRWeb/ -- CobbleStone Software – the recognized Leader in contract lifecycle management (CLM) according to the SPARK Matrix™ 2022 report – has released a comprehensive guide detailing the importance of Non-Disclosure Agreements (NDAs) and how they relate to many business relationships.
  • This guide focuses on the basics of NDAs, what were to happen if the terms of an NDA were violated, and how the correct contract management software can help with the creation and management of NDAs.
  • "As NDAs are a unique type of agreement, this free guide serves as a crash course into non-disclosure agreements and how they can be managed with contract management software."